Literature DB >> 7544845

Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia.

T L Tammela1, M J Kontturi.   

Abstract

PURPOSE: We assess the long-term effects of finasteride on bladder outlet obstruction and symptoms in the treatment of patients with benign prostatic hyperplasia.
MATERIALS AND METHODS: Of the original 36 patients assigned to treatment with 5 mg. finasteride daily (group 1) or placebo (group 2) for 6 months 27 completed an open extension study of 5 mg. finasteride for 4 more years. The possible relief of bladder outlet obstruction was monitored with repeated pressure-flow studies at baseline, 6 months and 4.5 years.
RESULTS: The treatment resulted in a further slight decrease in detrusor pressure at maximum flow rate in group 1 and a significant decrease in group 2 during the 4-year period, whereas improvement in maximum flow rate did not achieve statistical significance. Concomitantly, there was a significant improvement in obstructive and irritative symptoms.
CONCLUSIONS: Finasteride decreases bladder outlet obstruction moderately and only occasionally relieves it completely. However, the decrease in obstruction achieved in many patients is sufficient to improve the symptoms significantly. The beneficial effect is long-lasting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544845

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.

Authors:  Hu Zhang; Daniel M Frendl; Zongwei Wang; Aria F Olumi
Journal:  J Urol       Date:  2020-03-13       Impact factor: 7.450

Review 2.  [Primary and secondary prevention of benign prostatic hyperplasia: current knowledge and implications for clinical management].

Authors:  M Oelke; S Madersbacher
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

3.  Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it.

Authors:  Sebastiano Spatafora; Antonio Casarico; Andrea Fandella; Caterina Galetti; Rodolfo Hurle; Elisa Mazzini; Ciro Niro; Massimo Perachino; Roberto Sanseverino; Giovanni Luigi Pappagallo
Journal:  Ther Adv Urol       Date:  2012-12

Review 4.  Benign prostatic hyperplasia. Practical treatment guidelines.

Authors:  T Tammela
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 5.  [Drug therapy for benign prostatic hyperplasia. Systematic overview].

Authors:  R Berges; K Höfner
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

Review 6.  Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 7.  A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.

Authors:  P Ekman
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

8.  Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.

Authors:  Angela B Smith; Culley C Carson
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

Review 9.  Finasteride for benign prostatic hyperplasia.

Authors:  James Tacklind; Howard A Fink; Roderick Macdonald; Indy Rutks; Timothy J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 10.  Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons.

Authors:  G J Wise; E O Md
Journal:  Curr Urol Rep       Date:  2001-08       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.